Christopher Accettella Acquires 1,190 Shares of BlackRock Health Sciences Term Trust (NYSE:BMEZ) Stock

BlackRock Health Sciences Term Trust (NYSE:BMEZ) Portfolio Manager Christopher Accettella purchased 1,190 shares of BlackRock Health Sciences Term Trust stock in a transaction dated Thursday, January 11th. The shares were purchased at an average cost of 15.17 per share, with a total value of 18,052.30. Following the acquisition, the portfolio manager now owns 4,070 shares of the company’s stock, valued at approximately 61,741.90. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

BlackRock Health Sciences Term Trust Trading Up 0.8 %

Shares of NYSE:BMEZ opened at 15.89 on Monday. BlackRock Health Sciences Term Trust has a fifty-two week low of 12.93 and a fifty-two week high of 16.59. The company’s 50-day moving average price is 15.86 and its 200 day moving average price is 15.52.

BlackRock Health Sciences Term Trust Announces Dividend

The firm also recently disclosed a monthly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Tuesday, October 15th will be given a dividend of $0.176 per share. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $2.11 annualized dividend and a dividend yield of 13.29%.

Institutional Trading of BlackRock Health Sciences Term Trust

Several large investors have recently added to or reduced their stakes in BMEZ. Sessa Capital IM L.P. increased its holdings in shares of BlackRock Health Sciences Term Trust by 27.1% during the second quarter. Sessa Capital IM L.P. now owns 1,853,022 shares of the company’s stock valued at $28,462,000 after purchasing an additional 395,288 shares during the period. Almitas Capital LLC increased its stake in BlackRock Health Sciences Term Trust by 89.3% during the 2nd quarter. Almitas Capital LLC now owns 1,761,943 shares of the company’s stock valued at $27,063,000 after buying an additional 831,025 shares during the period. Karpus Management Inc. raised its position in shares of BlackRock Health Sciences Term Trust by 14.9% during the 1st quarter. Karpus Management Inc. now owns 1,398,681 shares of the company’s stock worth $22,924,000 after buying an additional 181,092 shares in the last quarter. Lazard Asset Management LLC lifted its stake in shares of BlackRock Health Sciences Term Trust by 24.3% in the 1st quarter. Lazard Asset Management LLC now owns 798,962 shares of the company’s stock worth $13,094,000 after acquiring an additional 156,417 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of BlackRock Health Sciences Term Trust by 66.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 399,964 shares of the company’s stock valued at $6,143,000 after acquiring an additional 159,401 shares in the last quarter.

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.